STAAR Surgical Company (STAA) Stock Analysis & Winston Score

STAAR Surgical makes tiny lenses that eye doctors implant inside the eye to fix vision problems like nearsightedness. Its main product is called the Implantable Collamer Lens, or ICL, which is placed in the eye without removing the natural lens — unlike LASIK, which reshapes the cornea. The company sells primarily to ophthalmologists and eye clinics, competing in the vision correction market alongside laser surgery providers. STAAR earns revenue by selling its lenses directly to eye care professionals and hospitals, with no recurring subscription model — each procedure requires a new lens. The company operates globally, with a large share of sales coming from Asia, particularly China and India, where demand for vision correction is high. Its ICL technology has a meaningful clinical differentiation for patients who are not good candidates for laser surgery, but heavy reliance on the Chinese market creates concentration risk, especially given regulatory and economic uncertainty in that region.